Key Points
- United Therapeutics CEO Martine Rothblatt sold 8,000 shares on May 26 at an average price of $572.38, generating about $4.58 million. After the sale, she still held 40,513 shares, a 16.49% reduction in her stake.
- The stock was trading near $570.75 at the time of the report, close to its 52-week high of $609.35 and well above its 52-week low of $272.12. The company’s market cap was about $24.23 billion.
- United Therapeutics recently missed quarterly earnings expectations, reporting $5.82 EPS versus the $7.00 estimate, while revenue also came in slightly below forecasts. Despite that, analysts remain largely positive, with 11 Buy ratings and a consensus Moderate Buy target of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 8,000 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $572.38, for a total transaction of $4,579,040.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $23,188,830.94. This represents a 16.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
United Therapeutics Stock Performance
Shares of NASDAQ:UTHR opened at $570.75 on Thursday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company's fifty day moving average is $565.54 and its 200-day moving average is $514.75. The company has a market capitalization of $24.23 billion, a PE ratio of 21.07, a P/E/G ratio of 1.87 and a beta of 0.60.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the firm posted $6.63 EPS. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock worth $514,016,000 after buying an additional 70,829 shares during the last quarter. Bull Harbor Capital LLC bought a new stake in shares of United Therapeutics during the first quarter worth approximately $494,000. Strategic Investment Advisors MI raised its stake in shares of United Therapeutics by 20.5% during the first quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company's stock worth $5,782,000 after buying an additional 1,662 shares during the last quarter. Talon Private Wealth LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $3,038,000. Finally, Royal Bank of Canada grew its stake in shares of United Therapeutics by 3.3% during the first quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company's stock worth $35,075,000 after purchasing an additional 1,864 shares during the period. 94.08% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on UTHR. Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an "outperform" rating for the company in a research note on Thursday, May 7th. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $619.42.
View Our Latest Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
